Astellas Pharma Inc Enfortumab Vedotin Call Transcript
And thank you, everyone, for joining today's call. My name is Bernie Zeiher, and I'm the Chief Medical Officer at Astellas. And I'm joined here today by Dr. Steven Benner, who is our President of Development.
During our time today, we will provide an update on the current clinical and regulatory status of enfortumab vedotin, or EV, which we are developing in partnership with Seattle Genetics for patients with locally advanced or metastatic urothelial cancer.
First, I'll share some information about the mechanism of action, treatment landscape in metastatic urothelial cancer and an overview of our development program. Then I'll hand it over to Steve to discuss the data from the EV-103 study, which explored EV in combination with the PD-1 inhibitor, pembrolizumab. And that was -- this data was recently presented at the ESMO Congress in Barcelona by Dr. Christopher Hoimes of the Genitourinary Oncology Case Comprehensive Cancer Center at Case Western Reserve University.
I'm sure many of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
